The 2.4 mg dose, which became the standard dose carried forward into phase 3 trials, produced approximately 8% to 9% weight loss in 26 weeks
Depending on dose, 64100% of retatrutide-treated individuals achieved at least 5% weight loss (a common benchmark for clinical success) versus 27% on placebo
[5] [8] Animal studies have shown thyroid C-cell tumours (medullary thyroid carcinoma) with some GLP-1 receptor agonists, but there is no confirmed link in humans and this is not a formal contraindication in UK prescribing information
Most people benefit from injections every one to four weeks, but some may require more frequent doses to maintain optimal energy and wellness
"Glutathione reductase from bakers' yeast and beef liver"
It's a group of compounds known to have antioxidant, anti-inflammatory, and anti-viral properties